

AACR Special Conference in Cancer Research

ADVANCES IN PANCREATIC CANCER RESEARCH


September 15-18, 2024 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients.

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark, C, Copyright; OIP, Other Intellectual Property; O, Other

Last Name	First Name	All Relationships	Type	Role
Aguirre	Andrew	Reactive Biosciences, Revolution Medicines, Syros Therapeutics, Third Rock Ventures, LLC., Kestrel Therapeutics, Servier Pharmaceuticals LLC, quanta, T-knife Therapeutics, AstraZeneca, Riva Therapeutics, Mirati Therapeutics, Merck, Nimbus Therapeutics, Plexium, Inc	IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC	Speaker
Allen	Peter	No Relationships		Program Committee, Speaker
Arthur	Ronald	No Relationships		Staff
Ballaro	Riccardo	No Relationships		Speaker
Barjau	Guillem	No Relationships		Speaker
Biffi	Giulia	Amalus Therapeutics	FO	Speaker
Bischoff	Allison	No Relationships		Speaker
Bryant	Kirsten	SpringWorks Therapeutics, Verastem, Inc., Sky Foundation	GC, GC, IC	Speaker
Byrne	Katelyn	No Relationships		Speaker
Chio	Christine	No Relationships		Speaker
Commisso	Cosimo	Patent	P	Speaker
Counter	Christopher	Merlon , HUMACYTE	OBO, OIP	Speaker
Datta	Jashodeep	Cantargia AB Inc.	GC	Speaker
DeNardo	David	Verastem, Inc., Bristol Myers Squibb Company, Oncotarget, Laboratorios Pfizer Ltda.	GC, GC, IC, GC	Speaker
Der	Channing	Revolution Medicines, Mirati Therapeutics	GC, IC	Speaker




AACR Special Conference in Cancer Research

ADVANCES IN PANCREATIC CANCER RESEARCH

September 15-18, 2024 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Dougan	Stephanie	Bristol-Myers Squibb, Novartis	GC, GC	Program Committee, Speaker
Garcia	Cathy	No Relationships		Speaker
Goggins	Michael	No Relationships		Speaker
Gunaydin	Gurcan	ROSGen	S	Speaker
Harris	Chris	No Relationships		Speaker
Hendifar	Andrew	valar, Amgen, Exelixis, faraday pharmaceuticals, Bristol Myers Squibb Company, Varian Medical Systems, Inc., Regeneron, Pancreatic Cancer Action Network, Ipsen Biopharmaceuticals, Inc, PFIZER PHARMA GMBH	OBO, IC, IC, IC, IC, IC, IC, IC, IC, IC	Speaker
Hollingsworth	Michael	No Relationships		Program Committee, Speaker
Huffman	Brandon	Doximity, Loxo Oncology	S, IC	Speaker
Iyer	Matthew	No Relationships		Speaker
Janowitz	Tobias	No Relationships		Speaker
Kalaany	Nada	No Relationships		Speaker
Kimmelman	Alec	Vescor, rafael therapeutics, oncorev, Patent, Patent, Patent, Patent	SO, SO, IC, P, P, P, P	Program Committee, Speaker
Lee	Jae	No Relationships		Speaker
Lyssiotis	Costas	Odyssey Therapeutics	IC	Speaker
Mancias	Joseph	Third Rock Ventures, LLC., Novartis, Casma Therapeutics, Skyhawk Therapeutics	IC, GC, GC, IC	Speaker
Mandal	Saurabh	No Relationships		Speaker
Martinez-Saucedo	Diana	No Relationships		Speaker
Mehla	Kamiya	No Relationships		Speaker
O'Kane	Grainne	Takeda Pharmaceutical Company, AstraZeneca, AstraZeneca, Merck, Novartis Pharma	IC, GC, IC, IC, IC	Speaker
O'Reilly	Eileen	Arcus, Silenseed, Celgene Corporation, Rafael, Cend, AstraZeneca, BioNTech, Genentech, CytomX	GC, GC, GC, IC, IC, IC, GC, GC, IC	Speaker
Offringa	Rienk	Boehringer Ingelheim, Bayer Healthcare, Bayer Healthcare, Tcelltech	GC, GC, IC, IC	Speaker



AACR Special Conference in Cancer Research

ADVANCES IN PANCREATIC CANCER RESEARCH

September 15-18, 2024 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
O'Hara	Mark	Arcus Bioscience, Bristol-Myers Squibb, Celldex Therapeutics, Elicio Therapeutics, Geistlich Pharma North America Inc., Genmab, HiberCell, Merus, Natera, Revolution Medicine, Stand Up To Cancer, Verastem, Inc.	GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC	Speaker
Olive	Kenneth	Revolution Medicines, Patent	GC, P	Speaker
Oni	Tobiloba	No Relationships		Speaker
Pasca Di Magliano	Marina	No Relationships		Speaker
Pinto Medici	Natasha	No Relationships		Speaker
Post	Dean	No Relationships		Staff
Pratt	Erica	No Relationships		Speaker
Ruiz	Christian	No Relationships		Speaker
Sagara	Akiko	No Relationships		Speaker
Schoenfeld	Joshua	No Relationships		Speaker
Sherman	Mara	No Relationships		Speaker
Singh	Mallika	Revolution Medicines, Revolution Medicines	S, E	Speaker
Singh	Harshabad	AstraZeneca, Dewpoint therapeutics, Merck Sharp and Dohme	GC, IC, IC	Speaker
Thege	Fredrik	No Relationships		Speaker
Timpson	Paul	Amplia Therapeutics, Amplia Therapeutics	IC, P	Speaker
Towers	Christina	No Relationships		Speaker
Waters	Andrew	No Relationships		Speaker
Woods	Nicholas	No Relationships		Speaker
Yao	Wantong	Patent	P	Speaker
Zimmers	Teresa	U.S. Department of Veterans Affairs, PELEOS, Indiana University	E, IC, E	Speaker

All of the relevant financial relationships listed for these individuals have been mitigated.